The battle against heart disease is propelling growth in the Atherosclerosis Market. This market, which targets the buildup of plaque in arteries, is expected to reach a value of USD 59.5 billion by 2033. This translates to a steady increase with a Compound Annual Growth Rate (CAGR) of 2.8% from 2023 to 2033. The current market value sits at USD 45.1 billion in 2023.
Atherosclerosis is the narrowing of the vein as a result of plaque build-up. Atherosclerosis is a particular kind of arteriosclerosis (stiffening or solidifying of the artery walls). The illness disturbs the stream of blood around the body, posturing genuine cardiovascular entanglements.
Request a PDF Sample with the Latest Market Insights
https://www.futuremarketinsights.com/reports/sample/rep-gb-2523
Atherosclerosis begins when the endothelium gets to be harmed, permitting LDL cholesterol to aggregate in the artery wall. The body sends macrophage white platelets to tidy up the cholesterol. However some of the time the cells stall out there at the influenced site. After some time this outcome in plaque is developed, comprising of terrible cholesterol (LDL cholesterol) and macrophage white platelets.
The plaque obstructs the corridor, upsetting the stream of blood around the body. This possibly causes blood clusters that can bring about the existence of undermining conditions, for example, heart assault, stroke, and other cardiovascular ailments. Besides aging, aspects that upsurge the risk of atherosclerosis include High blood pressure, high cholesterol, diabetes, obesity, smoking or other tobacco use, family history of early heart disease, lack of exercise, and an unhealthy diet.
Atherosclerosis Market: Drivers and Restraints
The growing incidence of heart attacks due to atherosclerosis or coronary heart disease is expected to increase demand for atherosclerosis treatment products. The rise in the aging population is expected to propel demand over the forecast period. As per the CDC (Centers for Disease Control and Prevention), coronary illness accounts for around 610,000 deaths per year in the United States- roughly being responsible for 1 of every 4 deaths reported. Coronary illness is the most widely recognized kind of coronary illness, killing more than 370,000 individuals every year. This increase in the baby boomer population is expected to add to the patient pool of atherosclerosis and thus in turn increase demand for treatment over the forecast period.
The development in the atherosclerosis market is determined by expanded prevalence, obesity, sedentary lifestyle, hypertension, dyslipidemia, an especially decrease in high thickness cholesterol (HDL-C), and elevated cholesterol slim down. Medications to treat Atherosclerosis include statins, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers (BB), antiplatelets, calcium channel blockers (CCBs), and nitrates. With the dispatch of first-in-class pipeline molecules, for example, Yosprala (headache medicine and omeprazole), Praluent (alirocumab), Dalcetrapib (RG1658), Vorapaxar (SCH 530348), Canakinumab (ACZ885), Varespladib (A 002), Aliskiren, Generx, Xarelto (rivaroxaban), Anacetrapib (MK0859), and others are relied upon to get propelled in the forecasting period. New contestants in the atherosclerosis market have indicated expanded adequacy and security profiles along with the reduction of CHD risk factors. Atherosclerosis or coronary artery disease showcase likewise has two different methods of treatment, which are coronary artery bypass grafting (CABG) and angioplasty.
The CAD death rate is very high compared with different maladies because of coronary events connected with CAD, including myocardial infections (MI), angina, and strokes. In this way, the counteractive action of such events remains an undiscovered region of research and development for pharmaceutical organizations to bring novel medications into the market. However, the absence of definitive treatment, side effects, limited efficacy of the drugs available in the market, and dependency on symptom-based treatment in several cases are expected to hamper revenue growth of the atherosclerosis market over the forecast period.
Atherosclerosis Market: Overview
The global market for atherosclerosis is expected to witness robust growth owing to an increasing incidence rate of heart problems coupled with new treatment (branded and generic) approaches.
Atherosclerosis Market: Region-wise Outlook
Globally the atherosclerosis market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Japan, and the Middle East and Africa (MEA). North America and Western Europe are expected to be the leading markets in the global atherosclerosis market. Rising treatment options among the aging population, prescription rates, and the maturing worldwide population are additionally considered vital drivers for this market. High awareness and easily available diagnostic tests are expected to boost demand for RSV infection treatment products in these regions. Japan and APEJ are expected to follow next in terms of demand for the treatment of atherosclerosis market. Eastern Europe, Latin America, and MEA markets are also expected to witness above-average growth over the forecast period. The absence of population-based studies in developing countries is a major challenge in the assessment of RSV-related infections in these countries.
Atherosclerosis Market: Participants
- GlaxoSmithKline plc.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Isis Pharmaceuticals, Inc.
- Anthera Pharmaceuticals
- Novartis AG
- Sanofi
- Johnson and Johnson
- Bayer AG
Key Segments Profiled In The Atherosclerosis Industry Survey
Atherosclerosis Market by Therapy:
- Atherosclerosis Medications
- Cholesterol-lowering Medications
- Antiplatelet drugs and Anticoagulants
- Atherosclerosis Beta Blockers
- Diuretics or Water Pills
- Angiotensin Converting Enzyme (Ace) Inhibitors
- Other Atherosclerosis Treatment Therapies
Atherosclerosis Market by Surgery:
- Atherosclerosis Treatment through Bypass Surgery (Coronary Artery Bypass Grafting (CABG))
- Atherosclerosis Treatment through Angioplasty
- Atherosclerosis Treatment through Atherectomy
Atherosclerosis Market by Distribution Channel:
- Atherosclerosis Treatment in Hospitals
- Atherosclerosis Treatment via Pharmacies
- Atherosclerosis Treatment via Drug Stores
- Atherosclerosis Treatment via Retail Pharmacies
- Atherosclerosis Treatment in Clinics
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
